Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo

Authors: Hui Zhao, Xiaomeng Gu

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Esophageal squamous cell carcinoma (ESCC) is a prevalent fatal cancer worldwide, and the number of deaths due to this disease is increasing. Due to ESCC resistance to chemotherapy and radiation treatment, new therapies are urgently needed for the improvement of ESCC patient clinical outcomes.

Methods

Eca-109 and TE-1 cells were transfected with 100 nM IGF-1r siRNA, and a combination of IGF-1r siRNA and radiation therapy was tested in vitro and in vivo. The effects of IGF-1r siRNA were determined through Western blotting and flow cytometry experiments.

Results

After radiotherapy, the number of IGF-1r siRNA-transfected Eca-109 cells decreased by approximately 67.3%, and a 78.9% reduction was observed in the transfected TE-1 cells. In addition, the Eca-109 and TE-1 cells that were irradiated following IGF-1r knockdown contained 16.2% and 20.3% apoptotic cells, respectively.

Conclusions

The results of the current study suggest that IGF-1r knockdown may enhance the radiation sensitivity of ESCC and increase the therapeutic effects of radiation both in vitro and in vivo. These results provide strong evidence that the targeted application of siRNA will enable the development of new therapeutic strategies for the clinical treatment of ESCC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shang L, Wang M: Molecular alterations and clinical relevance in esophageal squamous cell carcinoma. Front Med. 2013, 7: 401-410. 10.1007/s11684-013-0286-y.CrossRefPubMed Shang L, Wang M: Molecular alterations and clinical relevance in esophageal squamous cell carcinoma. Front Med. 2013, 7: 401-410. 10.1007/s11684-013-0286-y.CrossRefPubMed
2.
go back to reference Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H: Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013, 23: 233-242. 10.2188/jea.JE20120162.CrossRefPubMed Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H: Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013, 23: 233-242. 10.2188/jea.JE20120162.CrossRefPubMed
3.
go back to reference Thallinger CM, Kiesewetter B, Raderer M, Hejna M: Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma. Anticancer Res. 2012, 32: 4609-4627.PubMed Thallinger CM, Kiesewetter B, Raderer M, Hejna M: Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma. Anticancer Res. 2012, 32: 4609-4627.PubMed
4.
go back to reference Stoner GD, Wang LS, Chen T: Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol. 2007, 224: 337-349. 10.1016/j.taap.2007.01.030.PubMedCentralCrossRefPubMed Stoner GD, Wang LS, Chen T: Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol. 2007, 224: 337-349. 10.1016/j.taap.2007.01.030.PubMedCentralCrossRefPubMed
5.
go back to reference Nakajima M, Kato H: Treatment options for esophageal squamous cell carcinoma. Expert Opin Pharmacother. 2013, 14: 1345-1354. 10.1517/14656566.2013.801454.CrossRefPubMed Nakajima M, Kato H: Treatment options for esophageal squamous cell carcinoma. Expert Opin Pharmacother. 2013, 14: 1345-1354. 10.1517/14656566.2013.801454.CrossRefPubMed
6.
go back to reference Xie L, Song X, Yu J, Wei L, Song B, Wang X, Lv L: Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs. J Exp Clin Cancer Res. 2009, 28: 68-10.1186/1756-9966-28-68.PubMedCentralCrossRefPubMed Xie L, Song X, Yu J, Wei L, Song B, Wang X, Lv L: Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs. J Exp Clin Cancer Res. 2009, 28: 68-10.1186/1756-9966-28-68.PubMedCentralCrossRefPubMed
7.
go back to reference Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y: Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. 2012, 18: 5144-5153. 10.1158/1078-0432.CCR-12-0701.CrossRefPubMed Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y: Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. 2012, 18: 5144-5153. 10.1158/1078-0432.CCR-12-0701.CrossRefPubMed
8.
go back to reference Wang XC, Tian LL, Tian J, Li D, Wang Y, Wu H, Zheng H, Meng AM: Overexpression of Cks1 increases the radiotherapy resistance of esophageal squamous cell carcinoma. J Radiat Res. 2012, 53: 72-78. 10.1269/jrr.11090.CrossRefPubMed Wang XC, Tian LL, Tian J, Li D, Wang Y, Wu H, Zheng H, Meng AM: Overexpression of Cks1 increases the radiotherapy resistance of esophageal squamous cell carcinoma. J Radiat Res. 2012, 53: 72-78. 10.1269/jrr.11090.CrossRefPubMed
9.
go back to reference Chen J, Kwong DL, Cao T, Hu Q, Zhang L, Ming X, Chen J, Fu L, Guan X: Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis Esophagus. 2013, 10: 12088- Chen J, Kwong DL, Cao T, Hu Q, Zhang L, Ming X, Chen J, Fu L, Guan X: Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis Esophagus. 2013, 10: 12088-
10.
go back to reference Bellini MF, Silva AE, Varella-Garcia M: Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques. Genet Mol Biol. 2010, 33: 205-213. 10.1590/S1415-47572010005000028.PubMedCentralCrossRefPubMed Bellini MF, Silva AE, Varella-Garcia M: Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques. Genet Mol Biol. 2010, 33: 205-213. 10.1590/S1415-47572010005000028.PubMedCentralCrossRefPubMed
11.
go back to reference He LR, Liu MZ, Li BK, Rao HL, Deng HX, Guan XY, Zeng YX, Xie D: Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009, 100: 1591-1596. 10.1111/j.1349-7006.2009.01224.x.CrossRefPubMed He LR, Liu MZ, Li BK, Rao HL, Deng HX, Guan XY, Zeng YX, Xie D: Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009, 100: 1591-1596. 10.1111/j.1349-7006.2009.01224.x.CrossRefPubMed
12.
go back to reference Li SH, Huang EY, Lu HI, Huang WT, Yen CC, Huang WC, Chen CH: Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2012, 144: 1352-1359. 10.1016/j.jtcvs.2012.06.049.CrossRefPubMed Li SH, Huang EY, Lu HI, Huang WT, Yen CC, Huang WC, Chen CH: Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2012, 144: 1352-1359. 10.1016/j.jtcvs.2012.06.049.CrossRefPubMed
14.
go back to reference Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE, Reynolds JV, Pidgeon GP, Lysaght J: IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol. 2012, 107: 196-204. 10.1038/ajg.2011.417.CrossRefPubMed Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE, Reynolds JV, Pidgeon GP, Lysaght J: IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol. 2012, 107: 196-204. 10.1038/ajg.2011.417.CrossRefPubMed
15.
go back to reference Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y, Piao W, Nosho K, Arimura Y, Shinomura Y, Hosokawa M, Lee CT, Carbone DP, Imai K: Insulin - like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 2007, 28: 947-956.CrossRefPubMed Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y, Piao W, Nosho K, Arimura Y, Shinomura Y, Hosokawa M, Lee CT, Carbone DP, Imai K: Insulin - like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 2007, 28: 947-956.CrossRefPubMed
16.
go back to reference Adachi Y, Ohashi H, Imsumran A, Yamamoto H, Matsunaga Y, Taniguchi H, Nosho K, Suzuki H, Sasaki Y, Arimura Y, Carbone DP, Imai K, Shinomura Y: The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma. Tumour Biol. 2014, 35: 973-985. 10.1007/s13277-013-1131-2.CrossRefPubMed Adachi Y, Ohashi H, Imsumran A, Yamamoto H, Matsunaga Y, Taniguchi H, Nosho K, Suzuki H, Sasaki Y, Arimura Y, Carbone DP, Imai K, Shinomura Y: The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma. Tumour Biol. 2014, 35: 973-985. 10.1007/s13277-013-1131-2.CrossRefPubMed
17.
go back to reference Luo M, Shen D, Zhou X, Chen X, Wang W: MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery. 2013, 153: 836-847. 10.1016/j.surg.2012.12.004.CrossRefPubMed Luo M, Shen D, Zhou X, Chen X, Wang W: MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery. 2013, 153: 836-847. 10.1016/j.surg.2012.12.004.CrossRefPubMed
18.
go back to reference Sukka-Ganesh B, Mohammed KA, Kaye F, Goldberg EP, Nasreen N: Ephrin- A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene. BMC Cancer. 2013, 12: 309-CrossRef Sukka-Ganesh B, Mohammed KA, Kaye F, Goldberg EP, Nasreen N: Ephrin- A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene. BMC Cancer. 2013, 12: 309-CrossRef
19.
go back to reference Fernandez MC, Martin A, Venara M, Calcagno Mde L, Sansó G, Quintana S, Chemes HE, Barontini M, Pennisi PA: Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2013, 79: 623-630. Fernandez MC, Martin A, Venara M, Calcagno Mde L, Sansó G, Quintana S, Chemes HE, Barontini M, Pennisi PA: Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2013, 79: 623-630.
20.
go back to reference Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, Karasmanis I, Leva S, Angouridakis N, Vlachtsis K, Nikolaou A, Konstantinidis I, Fountzilas G: Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One. 2013, 8: e54048-10.1371/journal.pone.0054048.PubMedCentralCrossRefPubMed Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, Karasmanis I, Leva S, Angouridakis N, Vlachtsis K, Nikolaou A, Konstantinidis I, Fountzilas G: Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One. 2013, 8: e54048-10.1371/journal.pone.0054048.PubMedCentralCrossRefPubMed
Metadata
Title
Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo
Authors
Hui Zhao
Xiaomeng Gu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-325

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue